A Randomised, Cross-over Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push

Trial Profile

A Randomised, Cross-over Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push

Active, no longer recruiting
Phase of Trial: Phase III/IV

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Immunodeficiency disorders
  • Focus Therapeutic Use
  • Acronyms GAN-06
  • Sponsors Octapharma
  • Most Recent Events

    • 01 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 07 Feb 2017 Planned number of patients changed from 30 to 40.
    • 06 Jul 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top